ANA4CKD - Randomized multicenter double-blind controlled trial comparing anakinra to prednisone for gout flare in patients with chronic kidney disease stage 4-5 or kidney transplantation
This study, called ANA4CKD, is comparing two medicines, anakinra and prednisone, to see which is better at treating sudden, painful gout attacks. It focuses on people who have advanced kidney disease, are on dialysis, or have had a kidney transplant. Both men and women over 18 can take part. Some participants will receive anakinra, some will receive prednisone, and others will get a dummy treatment (placebo). The main aim is to check if anakinra helps reduce pain more effectively within three days compared to prednisone. Researchers will also look at how quickly people get better, how long they need treatment, and if there are any side effects, including serious ones like infections or heart problems.
At a glance
What is this study about?
This research study, known as ANA4CKD, is designed to find the best way to treat painful gout flares for people who are also dealing with serious kidney problems or have had a kidney transplant. Gout is a type of arthritis that causes sudden, severe joint pain. When you have kidney issues, treating gout can be tricky because some common medications might not be safe. This study is comparing two specific treatments: anakinra and prednisone. Both are known to help with inflammation, but researchers want to see which one is more effective and safer for this particular group of patients.
The main goal is to compare how well these two medications reduce pain during a gout attack. Participants will be closely monitored, and their pain levels will be checked regularly, especially within the first few days of treatment. Researchers will also look at how quickly symptoms improve, how long the treatment is needed, and whether patients experience any side effects. These side effects could range from minor reactions at the injection site to more serious health concerns like infections or heart issues.
By carefully studying these two treatments, the research team hopes to provide doctors with clearer guidelines on how to best help patients who suffer from gout flares alongside kidney disease. This could lead to more effective and safer treatment options, improving the quality of life for many people in a similar situation.
Key takeaways
- This study compares two treatments for gout flares in people with kidney disease or kidney transplants.
- It aims to find out which treatment is safer and more effective at reducing pain.
- Participants will receive either anakinra, prednisone, or a placebo.
- The main focus is on pain reduction within the first few days and monitoring for side effects.
- The study lasts for one month, with close medical supervision.
- You won't know which treatment you are receiving until the study is over.
Who may be eligible?
You might be able to join this study if you are 18 years old or older and are currently experiencing a painful gout attack that has not yet been treated. It's really important that you have certain kidney conditions.
Specifically, you need to have advanced kidney disease (called stage 3b, 4, or 5), be receiving dialysis, or have had a kidney transplant. Both men and women can take part in this research.
Your doctor will check your medical history and current health to make sure you fit all the requirements for this study.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you currently having a gout attack that hasn't been treated yet?
- Do you have advanced kidney disease (stage 3b, 4, or 5), are you on dialysis, or have you had a kidney transplant?
- Are you able to commit to the study visits and follow-up for about one month?
What does participation involve?
If you decide to participate, you will receive either one of the study medications (anakinra or prednisone) or a placebo (a dummy treatment that looks like the real medicine but contains no active drug). You won't know which one you're getting, nor will your doctors, until after the study is complete. You will have regular check-ups, and your pain levels will be recorded, mainly over the first three to five days. We'll also be monitoring how quickly your gout improves and if you experience any side effects. This includes looking at things like injection site reactions, any changes in your blood tests (like certain cells), or more serious health issues. We'll also track any hospital stays, use of pain relief, and how long you might be off work. The study will continue to monitor you for one month.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is gout?
Gout is a type of arthritis that causes sudden, very painful swelling and redness in joints, usually in the big toe.
Why are kidney problems important in this study?
Many gout medications can have side effects on the kidneys, so this study is looking for safer and more effective treatments for people who already have kidney disease or a transplant.
What is a 'placebo'?
A placebo is a dummy treatment, like a sugar pill or a saline injection. It looks exactly like the real medicine but doesn't contain any active drug. It helps researchers compare if the actual drug is better than no treatment.
Will I know which treatment I'm getting?
No, this is a 'blinded' study, meaning neither you nor your doctors will know if you're receiving anakinra, prednisone, or the placebo. This helps make the study results fair.
How long will I be involved in the study?
While the main pain evaluation is in the first few days, your health will be monitored for about one month after starting treatment in the study.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.